Skip to content

A human study to evaluate the seapolynol (Ecklonia cava extract) on postprandial glucose level and safety in healthy subjects

A human study to evaluate the seapolynol (Ecklonia cava extract) on postprandial glucose level and safety in healthy subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0001607
Enrollment
32
Registered
2015-08-31
Start date
2015-07-28
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : After 1-week run-in period, subjects are randomly assigned to control group or Seapolynol (Ecklonia cava) extract group. Control group takes placebo and test group takes Seapolyno

Sponsors

Ewha Womans University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subject who voluntarily agrees to participate and sign in informed consent form 2) Age: 20 years = Age < 40 years 3) fasting blood glucose < 126mg/dL 4) Subject who observes the study-instruction for intervation period

Exclusion criteria

Exclusion criteria: 1) Continuous consumption of drug that affect glucose metabolism, inflammation, antioxidative capacity and lipid metabolism or dietary supplement or oriental medicine within 4 weeks before the first visit 2) Consumption of anticoagulant within 4 weeks before the first visit 3) BMI=18.5 or BMI=30 4) Following diseases : ? Diabetes, liver dysfunction, renal dysfunction, cardiovascular diseases (hypertension(= 140/90 mmHg), stroke, etc.), thyroid diseases ? Mental diseases such as depression, schizophrenia, alcoholism , drug addiction ? Wasting diseases such as malignant tumor etc., and severe muscular skeletal disease ? asthma and allergic diseases 5) Chronic smoker (= 20 cigarettes / day) 6) Excessive exercise (= 10 hours / week) 7) Subjects who controlling body weight or subjects who have changed of body weight more than 4kg within 4 weeks before the first visit 8) Subjects with hypersensitivity to test materials 9) Participation in other human study within 4 weeks before the first visit 10) Pregnant or lactating women 11) Any condition that the principal investigator believes may put the subjects at undue risk

Design outcomes

Primary

MeasureTime frame
Markers of glucose metabolism

Secondary

MeasureTime frame
Markers of antioxidant status and oxidative stress, etc.

Countries

Korea, Republic of

Contacts

Public ContactYoungsook Ahn

Ewha Womans University

verdancys@naver.com

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026